SCHEMBL10274452

SCHEMBL10274452

COC(=O)Cc1cn(Cl)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ USP2 O75604 1/20 0.38
▸ HSP90AB1 P08238 1/20 0.37
▸ MAPT P10636 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ TP53 P04637 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP4F2 P78329 1/20 0.35
▸ CYP4A11 Q02928 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13563916 0.81 CYP2C9 (0.46) KDM4EALDH1A1USP2HSP90AB1MAPT
SCHEMBL18098599 0.79 KDM4E (0.40) KDM4EALDH1A1USP2HSP90AB1MAPT
SCHEMBL46947 0.78 GABRA5 (0.35) KDM4EALDH1A1POLBHPGDGAA
SCHEMBL10137877 0.76 CPB2 (0.52) KDM4EALDH1A1USP2KDM5B
SCHEMBL8865798 0.74 CDK5 (0.54) KDM4EALDH1A1KMT2AKDM5BLMNA
SCHEMBL19402101 0.74 ALDH1A1 (0.45) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL8865591 0.73 CDK5 (0.42) ALDH1A1USP2SMN1; SMN2KDM5BLMNA
SCHEMBL14551478 0.72 CPB2 (0.39) KDM4EALDH1A1USP2MEN1KMT2A
SCHEMBL7256301 0.72 FGFR1 (0.38) KDM4EALDH1A1USP2HSP90AB1MAPT
SCHEMBL31006001 0.71 KDM4E (0.37) KDM4EALDH1A1USP2RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2591354-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2016-09-07 — — EP disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 — — US disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC10A2, SLC34A2, SLC34A3 KDM4E 4411/4885ALDH1A1 3332/4885USP2 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback